A link between chronic hepatitis C virus (HCV) infection and low-grade B-cell lymphomas has been suggested by epidemiological studies. Marginal zone lymphomas (MZLs) including splenic lymphomas with villous lymphocytes are among the most frequently reported subgroups in the setting of chronic HCV infection. In this study, we examined the effect of antiviral treatment in eight patients with HCV-associated MZL. We found that five out of eight patients have responded to interferon alpha and ribavirin. In some cases, hematologic responses were correlated to virologic responses. In addition, we report a case of large granular lymphocyte leukemia occurring in association with MZL and HCV, and responding to interferon and ribavirin. We suggest that there is an etiologic link between HCV and antigen-driven lymphoproliferative disorders.
Introduction
Approximately 70% of patients with acute hepatitis C virus (HCV) infection become chronically infected and are at risk of developing complications like immune manifestations, cirrhosis and hepatocellular carcinoma. Initially evoked by epidemiological studies, the idea of a causal role of HCV also in some Bcell lymphomas emerges.
The first epidemiological studies, in the mid-1990s, were conducted in Italy where the prevalence of HCV infection is particularly high in some areas. [1] [2] [3] [4] [5] [6] The studies showed an increased prevalence of B-cell lymphomas among HCV-infected people but their results were contradictory to subsequent studies [7] [8] [9] [10] [11] [12] in countries with lower HCV infection prevalence. Nevertheless, positive results on association between HCV and B-cell lymphomas have also been reported outside Italy. [13] [14] The major pitfall in the interpretation of both results was the small size of samples. More recently, one prospective cohort study in Northern California 15 and two case-control studies, one in the USA 16 and one in Italy, 17 tried to address the question in large cohorts of patients. The first found that HCV infection did not precede at significant rates the development of B-cell lymphoproliferative disorders, while the two others did show a significant association between HCV and lymphomas.
In the latter study, 17 HCV-associated lymphomas were mainly marginal zone lymphomas (MZLs) and lymphoplasmacytic lymphomas, both of which are indolent B-cell lymphomas. Among MZLs, splenic subtype was found to be the most frequently associated to HCV. 18 Pathophysiological studies provided further evidence. Translocation t(14;18) and monoclonal IgH rearrangement were found in a substantial number of HCV-infected individuals, 19, 20 and further clonality studies showed a continuum between these clonal states and overt lymphoproliferative disease. Anti-HCV antibodies, the monoclonal compound of type II cryoglobulinemia and the lymphoma's immunoglobulins were found to be part of the same phenomenon, that is, the immunological response to HCV antigens. [21] [22] [23] [24] [25] [26] [27] [28] Moreover, interaction between the virus and the cell surface activates STAT3 and leads to cellular transformation. 29 Finally, recent research showed that tumoral HCV-infected B cells have an increased rate of mutations of IgH, BCL-6, P53 and b-catenin. 30 These findings strongly support the concept of HCV-induced lymphomagenesis.
The clinical implication is that antiviral strategies could influence the natural history of these lymphomas. Thus, the therapeutic implications of such a hypothesis are very important. Our knowledge of the effects of antiviral treatment on HCV-associated lymphomas is very limited. Only a few therapeutic studies on 15 patients in total are published so far. 18, [31] [32] [33] [34] In this study, we have examined the responses to antiviral treatment of eight additional patients with HCVassociated MZL.
Materials and methods
Patients with MZL were selected upon the criteria of positive HCV serology, absence of concomitant chemotherapy and absence of HIV coinfection. HCV serology was systematically performed in all patients with lymphoma seen in Cochin hospital from 1998 to 2002. The WHO classification distinguishes three subtypes of MZL based on anatomical and histopathological criteria: 35 splenic MZL with or without villous lymphocytes, nodal MZL with or without monocytoid cells and MZL of the mucosa-associated lymphoid tissue (MALT) type. For a better description of clinical presentation of HCV-associated MZL, we also used in this study the classification of Berger et al, 36 who separate four clinical subtypes of non-MALT MZL: splenic, nodal, disseminated (splenic and nodal) and leukemic (not splenic or nodal). Three cases (patients 2, 4 and 6) were identified retrospectively, and the subsequent five patients (1, 3, 5, 7 and 8) were identified prospectively. Median follow-up from introduction of antiviral treatment was 38.5 months (range 6-83 months). PCR for bcl2-IgH, IgH and TCR gamma rearrangement was performed, when mentioned, as previously described. 37, 38 HCV serology was determined by two ELISA tests of third generation. HCV RNA was quantified by RT-PCR (Amplicor HCV, Roche). Complete hematologic remission (CR) was defined as the disappearance of all clinical evidence of the lymphoma. Partial response was defined as 450% regression of lymphoma mass. Sustained and partial virologic response (SVR, PR) were defined by undetectable HCV RNA for more than 26 months after end of treatment and more than one-half reduction of initial viral load with detectable HCV RNA, respectively.
Case reports
We have identified 17 cases of HCV seropositivity among 360 B-cell lymphomas, nine of which were diffuse large cell lymphomas and eight MZLs (including splenic lymphoma with villous lymphocytes). The percentage of low-grade lymphomas was 17.4% (60/343) in HCV-negative patients and 47% (8/17) in HCV-positive patients, and this difference was significant (Po0.001). Thus, MZLs were more frequent in HCV-positive patients than in the general population of HCV-negative patients. Patients' characteristics and response to antiviral treatment are summarized in Tables 1 and 2 . 
Antiviral treatment in HCV-associated MZL C Kelaidi et al
Patient 1 was a 46-year-old man referred for a central immune neutropenia with polyclonal large granular lymphocytes (LGLs) CD3 þ CD8 þ CD56À. Interferon (IFN) alpha 3 MU thrice a week and ribavirin 1200 mg per day were administered for 10 months with no effect on viral load, neutropenia or LGLs. On the contrary, newly diagnosed type I diabetes completely remitted and the patient no longer needed insulin. At 6 months after interferon alpha and ribavirin discontinuation, newly appearing digestive symptoms led to the diagnosis of ileal MZL of the MALT type. Of interest, IgH rearrangement studies by PCR revealed two different clones: one single clone in peripheral blood and bone marrow; and a different single clone on ileal biopsy. Bcl-2 rearrangement was negative in ileum and bone marrow. PEG interferon 80 mg once per week and ribavirin 1200 mg per day were introduced and led to a significant reduction from 5.1 log IU/ml to 2.84 log IU/ml, although without negativation of HCV viral load. Complete hematologic remission was obtained with, notably, normalization of neutrophils and disappearance of LGLs. Relapse occurred 3 months after antiviral treatment discontinuation. Reintroduction of antiviral bitherapy led again to CR of lymphoma with parallel reduction of HCV viral load. The patient is currently under treatment.
Patient 2 was a 37-year-old woman diagnosed with splenic MZL with circulating villous lymphocytes. She underwent splenectomy without efficacy and then received interferon alpha alone 3 MU thrice per week for 18 months with complete virologic and hematologic remission. Lymphoma relapsed 18 months after discontinuation of interferon, while HCV RT-PCR remained negative. Relapse occurred in a disseminated form with mediastinal and abdominal lymph nodes and bronchial localization.
Patient 3, a 65-year-old man, had undergone a liver transplantation for chronic HBV and HCV infection with cirrhosis 8 years before admission. Treatment consisted of cyclosporin 150 mg per day, PEG interferon 80 mg per week and ribavirin 1000 mg per day for 5 years for HCV infection of the liver graft and HCV-related cirrhosis. HCV PCR remained positive under treatment. At 6 weeks after interferon and ribavirin discontinuation, autoimmune hemolytic anemia (AIHA) with cold agglutinins led to diagnosis of MZL on bone marrow biopsy, leukemic subtype since spleen and lymph nodes were not enlarged. EBV viral load was very weak and latent membrane protein was negative on immunohistochemistry. After initial control of AIHA with prednisone 2 mg/kg/day, PEG interferon alpha and ribavirin were reintroduced at the same dose and lymphocytosis returned to normal levels and remained so with a follow-up of 3 months. Bone marrow assessment after therapy was not performed. Unfortunately, viral load evolution is not available.
Patient 4, a 43-year-old, was diagnosed with duodenal MZL of the MALT type, localized. He had been contaminated with HCV 10 years before. Antiviral treatment consisted of PEG interferon alpha 80 mg once a week, ribavirin 1200 mg per day and amantadine hydrochloride 100 mg twice a day for only 3 weeks. HCV viral load became undetectable and remained so with a follow-up of 12 months. Digestive symptoms completely regressed as well as splenomegaly. The protein electrophoresis spike and cryoglobulin became undetectable and complement normalized. The patient declined further evaluation of hematological remission by duodenal biopsies.
Patient 5, a 41-year-old man, consulted for peripheral neutropenia at 0.180 Â 10 9 /l and hyperlymphocytosis at 8.280 Â 10 9 /l. HCV infection had occurred 20 years ago. Hyperlymphocytosis was made of LGLs of T-cell gamma/delta phenotype. Pan-B markers were negative on peripheral blood immunophenotyping. Surprisingly, PCR rearrangement studies on peripheral blood revealed double clonality T and B, that is, monoclonal TCR gamma rearrangement and monoclonal IgH rearrangement. Accordingly, bone marrow biopsy showed a diffuse infiltration by LGLs and a second pattern of focal infiltration by marginal zone lymphocytes CD20 þ CD79a þ kappa. Maturation of granulocytes was normal. The patient was diagnosed with LGL leukemia and splenic MZL associated with HCV infection. Under antiviral treatment by PEG interferon alpha 70 mg/week and ribavirin 700 mg/day for 12 months, HCV PCR became negative and LGLs disappeared. Immunophenotyping and polyclonal IgH rearrangement in peripheral blood confirmed the remission of the T-and B-cell lymphoproliferation, respectively. Neutrophils increased from 0.180 Â 10 9 / l to 1.400 Â 10 9 /l. Antiviral treatment is currently continuing. Patient 6 was an HCV and HBV coinfected 32-year-old man. HBV DNA was undetectable by PCR method and HIV serology was negative. Peripheral blood count was remarkable for hyperlymphocytosis made of polyclonal small B cells of marginal zone phenotype. At 6 months after a 6-month period of interferon alpha monotherapy 3 MU thrice per week with sustained viral response but no effect on lymphocytosis, a right renal mass was detected and infiltration by the same lymphocytes was evidenced in the spleen, liver, right kidney and Patient 7, a 66-year-old woman, was diagnosed with splenic MZL with villous lymphocytes. The immunophenotype was atypical in that CD5 was positive. Cyclin D1 expression on peripheral blood PCR was negative. PEG interferon alpha 80 mg once a week and ribavirin 800 mg per day for 18 months resulted in complete virological response but had no effect on lymphoma.
Patient 8, a 73-year-old woman, was diagnosed with splenic MZL with villous lymphocytes. Staging revealed abdominal (celiac and retroperitoneal) lymph nodes enlargement in addition to splenic involvement. Positive HCV serology had been discovered 12 years before and was retest positive on admission but qualitative HCV PCR was negative. The patient was coinfected by HBV. She was treated with PEG interferon alpha 80 mg once a week and ribavirin 800 mg per day for 6 months. No hematologic response was noted.
Discussion
We report here the response to antiviral treatment of a series of patients with lymphoma associated with HCV infection. Our results reveal multiple patterns of response and extend the use of antiviral treatment of HCV-associated lymphomas to the MZL group, beyond the splenic lymphoma with villous lymphocytes (SLVLs) group already described. 18, 31, 32, 34 Therapeutic studies in HCV-associated lymphomas have begun with the effect of interferon alpha on surrogate markers of clonal B lymphoid expansion in HCV infection, that is, type II cryoglobulinemia and clonal IgH and Bcl-2 rearrangement, in the absence of overt lymphoma. Mazzaro et al 39 treated with interferon 20 HCV-positive patients with cryoglobulinemia: three of four virologic responders attained hematologic remission. Zuckerman et al 40 reported the negativation under interferon of clonal IgH and Bcl-2 rearrangement in seven of nine and six of seven virologic responders, respectively, and similar results had been reported by Casato et al. 41 Finally, Giannelli et al 42 observed the disappearance of t(14;18) translocation under interferon-ribavirin in 15 of 30 HCVpositive patients without mixed cryoglobulinemia syndrome. In all three studies, molecular response was strongly correlated with virologic response, but the latter also emphasized the occurrence of t(14;18) negativation in some cases of partial or even null virologic response.
The first case of interferon treatment of an overt HCVassociated lymphoma was reported by Casato et al. 31 This lymphoma was of MZL type. Hermine et al 32 reported the first series of HCV-associated SLVLs treated by interferon with or without ribavirin: complete remission was achieved in eight of nine patients. Interferon had no effect in controls HCV-negative SLVLs. Both studies demonstrated a strong correlation between virologic and hematologic response and relapse. Nevertheless, hematologic responses were not accompanied by molecular remissions. Three recent studies also report on the use of antiviral treatment in HCV-associated lymphomas: Arcaini et al 18 and Pitini et al 34 report responses in two out of two splenic MZL each, while Levine et al 33 successfully treated a mantle-cell lymphoma.
Our series of HCV-associated lymphomas consists of two intestinal MZLs of the MALT type, four splenic MZLs, one disseminated and one leukemic subtype. The nodal subtype was not encountered. In the study of Arcaini et al, 18 nodal MZLs were indeed by far less associated with HCV than splenic MZLs.
LGL leukemia was associated with splenic MZL in one case and polyclonal LGLs were present in one more case. CD10ÀCD5ÀCD23À phenotype was concordant with previous studies 36 with the exception of one case of CD5 positivity. Bone marrow involvement and locoregional lymph nodes were frequent in the splenic subtype, as previously reported. 18, 36 Lymphoid infiltration of the liver occurred in one case, the one with bulk tumoral syndrome. Autoimmune phenomena were very frequent and various, and cryoglobulinemia was constant. All but one patient had a positive qualitative HCV PCR. We did not notice any association with a particular HCV genotype or histologic severity of HCV hepatitis, although in Italy an association between genotype 2 and prevalence of HCV-related lymphoma 43 has been reported. Translocation t(14;18) has been found in a greater prevalence in patients with chronic HCV infection than in HCV-uninfected individuals. 19, 20 IgH-Bcl2 rearrangement was negative in two and oligoclonal in one of the three cases tested here. We, therefore, cannot draw any conclusion as to its evolution under antiviral treatment. The case of oligoclonal bcl2 rearrangement in patient 6 is associated with partial trisomy 3. Oligoclonal bcl2 rearrangement and chromosome i(3q) are also encountered in persistent polyclonal lymphocytosis (PPLB). 44 Trisomy 3 is recurrent in MZL 45 and PPLB shares immunophenotypic characteristics with the normal CD27 compartment of the marginal zone. 46 Therefore, this particular case of HCVassociated lymphoid proliferation could represent a relationship between PPBL and MZL Antiviral treatment resulted in hematologic response in patients 1-5. A correlation between hematologic and virologic response was noted in some cases. Patient 1 demonstrated indeed a clearcut evolution with strict parallelism between lymphoma course and HCV viral load despite the absence of complete virologic response. Therefore, the persistence of detectable viral RNA may not be incompatible with hematologic response if a sufficient pressure is maintained by antiviral treatment on viral replication. Furthermore, the lymphoproliferative disorder of patient 3 manifested itself shortly after discontinuation of treatment despite the absence of virologic response, and then remitted upon reintroduction of antiviral treatment. On the contrary, patient 2 relapsed at distance from discontinuation of antiviral treatment while still in virologic remission. A secondary escape of lymphoid proliferation despite virologic control is thus possible. Interferon was ineffective in the sole patient with undetectable HCV RNA, whose treatment was based on the encouraging results of Hermine et al. 32 Therefore, even in cases where response is not correlated with HCV viral load or with qualitative HCV PCR, interferon does act by its antiviral property.
Our patients did not receive chemotherapy. Nevertheless, we do not suggest not adjoining chemotherapy in clinically aggressive disease at presentation. The one patient with disseminated disease (patient 6) had only splenomegaly at the onset of antiviral treatment and progressed secondarily in progressive disease. Another patient with HCV-associated disseminated MZL, not reported in this study, received chemotherapy in the first place because of B symptoms and bulky disease. Concerning treatment duration, we observed one early response but the majority of patients attained hematologic remission progressively and a length of at least 12 months seems Antiviral treatment in HCV-associated MZL C Kelaidi et al to be required. Moreover, a more prolonged treatment could have prevented relapse in patient 1 (since relapse occurred immediately after treatment discontinuation). Maintenance therapy seems therefore appropriate. We report the first case to our knowledge associating HCV infection, MZL and LGL leukemia of gamma/delta T-cell phenotype. An antigen-driven T-cell expansion hypothesis has been proposed to explain the pathogenesis of LGL leukemia. 47 LGLs expansion has also been observed in the setting of HIV and CMV infection. Our patient was negative for these viruses. Independent studies have showed that activation of STAT3 inhibits apoptosis of leukemic LGLs 47, 48 and that the core protein of HCV activates STAT3, which leads to cellular transformation. 29 An HCV antigen-driven process and/or a direct antiapoptotic effect of the virus on cytotoxic lymphocytes could have provoked the LGLs expansion in addition to MZLs in this case. The partial response of LGLs to antiviral treatment in parallel with the clearance of the virus and the presence of LGLs in two more cases further support this hypothesis. Nevertheless, an antiproliferative effect of interferon alpha on LGLs proliferation cannot be excluded although this effect has been reported only once 49 and the contrary would be expected on a physiologic basis. 50 The variability of clinical histories and responses supports the hypothesis of a multistep viral lymphomagenesis in the case of HCV. HCV seems to play an initiating role by antigenic drive of polyclonal and then gradually clonal B-cell expansion on the one hand, and on the other hand perhaps by direct interaction with landmark signaling pathways like STAT3, which leads to cellular transformation when activated by HCV core protein. A second molecular event, like bcl2 hyperexpression, could take over the initiating event and sustain the B-cell expansion, ultimately leading to tumorigenesis. Indeed, the persistent oligoclonal proliferation of patient 6 could be considered as an intermediate step in HCV-induced lymphomagenesis. HCV infection, the first event, would lead to polyclonal B-cell expansion and bcl2 hyperexpression and trisomy 3, the second event, would lead to the oligoclonal stage of proliferation. The multistep hypothesis could explain as to why in some advanced cases complete viral clearance is neither necessary nor sufficient for hematologic response or prevention of relapse. Accordingly, early treatment could be more efficient before molecular complexity and independence from virus are installed. Nevertheless, interferon might also act on a late molecular event and that could be the reason for the re-emergence of B-cell clone despite the absence of viral replication.
In conclusion, we report significant responses of HCVassociated MZL to antiviral treatment. Our results support the hypothesis of an etiologic relationship between lymphomas and chronic HCV infection, and encourage the use of antiviral treatment in these lymphomas. This relationship can be extended to MZL, and an HCV serology should be performed systematically as MZL is diagnosed. Maintenance treatment is probably needed. Further studies on larger populations are required to provide more evidence on the relationship between viral infection and B-cell lymphoma as well as on the modalities of antiviral treatment of lymphoma.
